Symbolbild · KI-generiert
VVT Med Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
VVT Med Inc is a medical device company, focused on developing and commercializing a range of minimally invasive technologies for treating varicose veins. VVT¿s research and development activities are based in Israel. The company proudly boasts three products within its portfolio that have achieved commercial production status and are currently available in the market. These products have undergone meticulous design processes, obtaining regulatory approvals across multiple countries.
Company description as published by the issuer via TMX Money.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| VVT Med Inc. | VVTM | TSXV | 11 Mio. USD |
| Pharmacielo Ltd. | PCLO | TSXV | 11 Mio. USD |
| Avicanna Inc. | AVCN | TSX | 12 Mio. USD |
| KDA Group Inc. | KDA | TSXV | 12 Mio. USD |
| Aurora Spine Corporation | ASG | TSXV | 11 Mio. USD |
| Pharmala Biotech Holdings Inc. | MDMA | CSE | 12 Mio. USD |
| Ynvisible Interactive Inc. | YNV | TSXV | 11 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.